keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NX-2127 (ETX2514 Triethylamine) 是一种口服有效的 BTK 抑制剂,可诱导细胞中突变的 BTKC481S 降解。NX-2127 具有有效的抗增殖活性,可抑制 BTKC481S 突变体 TMD8 细胞的增殖。NX-2127 有效催化 Ikaros (IKZF1) 和 Aiolos (IKZF3) 降解,作用浓度分别为 25 nM 和 54 nM。NX-2127 与免疫系统有关,刺激 T 细胞活化并增加原代人 T 细胞中 IL-2 的产生。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 987 | 现货 | ||
5 mg | ¥ 2,580 | 现货 | ||
10 mg | ¥ 3,970 | 现货 | ||
25 mg | ¥ 6,530 | 现货 | ||
50 mg | ¥ 8,890 | 现货 | ||
100 mg | ¥ 11,800 | 现货 | ||
500 mg | ¥ 23,800 | 现货 |
产品描述 | NX-2127 (ETX2514 Triethylamine) is an orally active BTK inhibitor that induces degradation of mutant BTKC481S in cells.NX-2127 has potent antiproliferative activity and inhibits the proliferation of BTKC481S mutant TMD8 cells.NX-2127 potently catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3) at 25 nM and 54 nM, respectively. NX-2127 is associated with the immune system, stimulating T cell activation and increasing IL-2 production in primary human T cells. |
体外活性 |
NX-2127 inhibits the proliferation of BTK-C481S mutant TMD8 cells with an EC50 value of <30 nM.[1] NX-2127 increases IL-2 production in primary human T cells.[1] |
体内活性 |
NX-2127 (1 mg/kg; oral; once daily for 14 days) showed efficient degradation of BTK in cynomolgus monkeys.[1] NX-2127 (oral administration) results in dose-proportional exposure and degradation of BTK in plasma to less than 10% of baseline levels in circulating and splenic B cells.[1] NX-2127 produces superior tumor growth inhibition (TGI) in WT TMD8 and C481S mutant xenograft models in mice.[1] |
别名 | NX2127, NX 2127 |
分子量 | 719.83 |
分子式 | C39H45N9O5 |
CAS No. | 2416131-46-7 |
keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (69.46 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.3892 mL | 6.9461 mL | 13.8922 mL | 34.7304 mL |
5 mM | 0.2778 mL | 1.3892 mL | 2.7784 mL | 6.9461 mL | |
10 mM | 0.1389 mL | 0.6946 mL | 1.3892 mL | 3.473 mL | |
20 mM | 0.0695 mL | 0.3473 mL | 0.6946 mL | 1.7365 mL | |
50 mM | 0.0278 mL | 0.1389 mL | 0.2778 mL | 0.6946 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
NX-2127 2416131-46-7 Angiogenesis Tyrosine Kinase/Adaptors BTK NX2127 NX 2127 Inhibitor inhibitor inhibit